Search Clinical Trials | Froedtert & the Medical College of Wisconsin

Keyword

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

29 results for "Cancer" and "Gastrointestinal Cancers"

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility

Protocol No

ADP-0000-001-SCR

Sub Category

Gynecologic Cancers

Prostate and Urologic Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Head and Neck Cancers

Gastrointestinal Cancers

A Phase II Trial of Nab-Paclitaxel plus Cisplatin plus Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to find out if the study drugs nab-paclitaxel, cisplatin, and
gemcitabine given together are safe and effective.

Protocol No

HRI-AX-CL-PANC-PI-13301

Sub Category

Gastrointestinal Cancers

A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

Protocol No

PFIZER-B7461009

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Endocrine Cancers

Breast Cancers

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Protocol No

ALLIANCE-A021502-ATOMIC

Sub Category

Gastrointestinal Cancers

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

Protocol No

AFT-25-COMET

Sub Category

Breast Cancers

A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors

ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors

Protocol No

ADP-0055-001-MAGE-A4-SURPASS

Sub Category

Gastrointestinal Cancers

Thoracic Cancers

Sarcoma

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

An Exploratory Study of Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance

Endocrine therapy before surgery to assess disease response and mechanisms of resistance in tumor cells

Protocol No

IIT-CHAUDHARY-ENDOCRINE

Sub Category

Breast Cancers

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A Phase 2 Randomized Multicenter Trial to Compare Hepatic Progression-free Survival Following Bland Embolization, Lipiodol Chemoembolization, and Drug-eluting Bead Chemoembolization of Neuroendocrine Liver Metastases

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

Protocol No

U-PENN-UPCC-01215-RETNET

Sub Category

Gastrointestinal Cancers

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Protocol No

ACCRU-SC-1601

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Eye/Orbital Cancers

Endocrine Cancers

Breast Cancers

Brain and Spine Cancers

Phase II Study of PD-1 Inhibition with Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy

This project is being done to assess the effectiveness of adding the drug Cemiplimab to the standard neoadjuvant chemotherapy regimen in patients with estrogen receptor and/or progesterone receptor positive, HER2 negative, or triple-negative invasive breast cancer.

Protocol No

IIT-CHAUDHARY-PD1-CEMIPLIMAB

Sub Category

Breast Cancers

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive HER2 Negative Breast Cancer: The ABC Trial

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Protocol No

ALLIANCE-A011502-ABC

Sub Category

Breast Cancers

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Protocol No

HOFFMANN-WO39608-MORPHEUS

Sub Category

Gastrointestinal Cancers

Early Phase/Multiple Disease Site Cancers

A Phase II Clinical Trial of GVAX Pancreas Vaccine (with Cyclophosphamide) in Combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients with Borderline Resectable Pancreatic Adenocarcinoma

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Protocol No

JH-J1756-IRB00130075-GVAX

Sub Category

Gastrointestinal Cancers

A Phase 3, Interventional, Randomized, Multicenter, Open-label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Protocol No

DECIPHERA-DCC-2618-03-002

Sub Category

Sarcoma

Gastrointestinal Cancers

Molecular Analysis for Therapy Choice (MATCH)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Protocol No

ECOG-EAY131-MATCH

Sub Category

Brain and Spine Cancers

Early Phase/Multiple Disease Site Cancers

Hematologic/Blood Related Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Eye/Orbital Cancers

Endocrine Cancers

Breast Cancers

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

Protocol No

ALLIANCE-A011202

Sub Category

Breast Cancers

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

TACE in Combination with Durvalumab & Bevacizumab Therapy in Locoregional HCC (EMERALD-1)

Protocol No

AZ-D933GC00001-EMERALD-1

Sub Category

Gastrointestinal Cancers

Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients with Localized Pancreatic Cancer

Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer

Protocol No

IIT-TSAI-PANC

Sub Category

Gastrointestinal Cancers

A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors

his clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients.

Protocol No

CYTEIR-CYT-0851-01-REFMAL639

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Sarcoma

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Breast Cancers

An Open-Label, Multiple-Dose, Dose- Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

This is a Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Protocol No

VMONCOLOGY-VMO-01C

Sub Category

Breast Cancers

Early Phase/Multiple Disease Site Cancers

Gastrointestinal Cancers